Stock Events

Stock Events

Syntara 

€0.02
0
-€0-6.82% Friday 06:15

Statistics

Day High
0.02
Day Low
0.02
52W High
0.04
52W Low
0.01
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

25FebExpected
Q4 2025
-0
0.33
0.66
1
Expected EPS
N/A
Actual EPS
-0.002089712233

People Also Follow

This list is based on the watchlists of people on Stock Events who follow UUDA.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap4.7B
CRISPR Therapeutics is involved in gene editing, a direct competitor in the biotechnology field focusing on genetic engineering like Syntara.
Editas Medicine
EDIT
Mkt Cap284.81M
Editas Medicine operates in the CRISPR technology space, making it a direct competitor in gene editing technologies.
Intellia Therapeutics
NTLA
Mkt Cap1.61B
Intellia Therapeutics is another key player in the CRISPR technology sector, competing directly with Syntara in gene editing applications.
Beam Therapeutics
BEAM
Mkt Cap2.79B
Beam Therapeutics uses base editing technology, a form of gene editing that competes with Syntara's CRISPR technology.
Sangamo Therapeutics
SGMO
Mkt Cap78.75M
Sangamo Therapeutics specializes in genomic medicine, including gene editing, directly competing with Syntara's offerings.
Alnylam Pharmaceuticals
ALNY
Mkt Cap40.77B
Alnylam Pharmaceuticals focuses on RNAi therapeutics, which are related to gene therapy and thus compete in the broader genetic medicine space with Syntara.
Ionis Pharmaceuticals
IONS
Mkt Cap12.1B
Ionis Pharmaceuticals is a leader in antisense technology, which is used to treat genetic disorders and competes with gene editing technologies.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.28B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for rare genetic diseases, competing in the same therapeutic areas as Syntara.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.45B
Vertex Pharmaceuticals incorporates CRISPR and other genetic technologies in developing treatments for diseases with significant unmet need, overlapping with Syntara's market.

About

Syntara Limited operates as a clinical-stage drug development company that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate, amsulostat, is being developed for the treatment of bone marrow cancer myelofibrosis and is in Phase 1c/2 studies for patients with myelodysplastic syndrome. The company also develops topical pan-LOX inhibitors with SNT-9465, which is in a Phase 1a/b study for hypertrophic scars; SNT-6302 for keloid scars; and SNT-4728 to treat sleep disorders and slow progression of neurodegenerative diseases by reducing neuroinflammation. In addition, it develops other drug candidates that target fibrotic and inflammatory diseases, including kidney fibrosis, MASH, pulmonary fibrosis, and cardiac fibrosis. The company was formerly known as Pharmaxis Ltd and changed its name to Syntara Limited in December 2023. Syntara Limited was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.
Show more...
CEO
Mr. Gary Jonathan Phillips BPharm, MBA
Employees
21
Country
Australia
ISIN
AU0000312480

Listings

STU
DE
UUDA.STU
MU
DE
UUDA.MU
AU
AU
SNT.AU
F
DE
UUDA.F

0 Comments

Share your thoughts

FAQ

What is Syntara stock price today?▼
The current price of UUDA.MU is €0.02 EUR — it has decreased by -6.82% in the past 24 hours. Watch Syntara stock price performance more closely on the chart.
What is Syntara stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Syntara stocks are traded under the ticker UUDA.MU.
When is the next Syntara earnings date?▼
Syntara is going to release the next earnings report on September 02, 2026.
What were Syntara earnings last quarter?▼
UUDA.MU earnings for the last quarter are -0 EUR per share, whereas the estimation was N/A EUR resulting in a N/A surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Syntara have?▼
As of April 30, 2026, the company has 21 employees.
In which sector is Syntara located?▼
Syntara operates in the Health & Wellness sector.
When did Syntara complete a stock split?▼
Syntara has not had any recent stock splits.
Where is Syntara headquartered?▼
Syntara is headquartered in Frenchs Forest, Australia.